Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for HCA Healthcare (HCA) is 6/10.
HCA Healthcare opened FY2026 with revenue up 4.3% year-over-year and adjusted diluted EPS up approximately 11%, while adjusted EBITDA grew almost 2% as an unusually mild respiratory season and a January winter storm together cut an estimated $180 million from EBITDA. The volume miss was concentrated in January (same-facility admissions rose 0.9% and ER visits 0.3%), but management said February and March rebounded toward the full-year 2% to 3% growth plan. A larger-than-expected net benefit of roughly $200 million from Medicaid supplemental payment programs (Georgia, the reinstated Texas Atlas program and Tennessee) largely offset the seasonal drag, even as the health-insurance-exchange shift cut exchange equivalent admissions about 15% for an estimated $150 million EBITDA impact in the quarter. Management reaffirmed full-year 2026 guidance, framing the first-quarter headwinds as temporal rather than structural and holding the $600 million to $900 million exchange-impact range and $400 million resiliency target unchanged.
Scored from HCA Healthcare’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $18.29B | +5.7% | $5.63 | -5.1% | 15.6% | 7.9% | $1.27B |
| FY2025 Q1 | $18.32B | +5.7% | $6.45 | +8.6% | 15.6% | 8.8% | $660M |
| FY2025 Q2 | $18.61B | +6.4% | $6.83 | +23.5% | 15.9% | 8.9% | $3.03B |
| FY2025 Q3 | $19.16B | +9.6% | $6.96 | +42.3% | 15.5% | 8.6% | $3.13B |
| FY2025 Q4 | $19.51B | +6.7% | $8.14 | +44.6% | 16.3% | 9.6% | $870M |
| FY2026 Q1 | $19.11B | +4.3% | $7.15 | +10.9% | 15.0% | 8.5% | $895M |
| FY2026 Q2 | $20.23B | +8.7% | $7.62 | +11.6% | 15.2% | 8.4% | $1.10B |